Mangoceuticals, INC

Mangoceuticals, Inc. announced a business combination agreement with Nuclea Energy Inc. to advance Nuclea's Morpheus microreactor technology.

Mangoceuticals, Inc. has entered into a subscription agreement with an accredited investor for the purchase of 850,000 shares of restricted common stock, raising $272,000.

Mangoceuticals, Inc. repriced CEO Jacob Cohen's stock options to $0.45 per share and filed a lawsuit seeking over $73 million against its former technology consultant, Clarity Ventures, Inc.

Mangoceuticals announced new data for its antiviral compound MGX-0024, showing zero respiratory-related mortality in large-scale poultry field trials and prophylactic benefits against H5N1.

Mangoceuticals reports significant initial success for its new $99/month injectable Testosterone Replacement Therapy program, boasting 336% month-over-month sales growth and a 54% reduction in customer acquisition costs.

Mangoceuticals, Inc. received a Nasdaq deficiency notice for failing to maintain a minimum bid price of $1.00 per share.

Mangoceuticals, Inc. reported a net loss of $3.4 million for the first quarter of 2026, with revenues declining compared to the prior year period.

Mangoceuticals, Inc. reported a significantly increased net loss for the third quarter and first nine months of 2025, driven by higher operating expenses and a drop in revenue, despite an improved cash position from financing activities.

Mangoceuticals, Inc. filed an amended quarterly report for Q2 2025, revealing increased net losses and significant stock-based compensation, alongside strategic intellectual property acquisitions and ongoing financing efforts.

Mangoceuticals, Inc. reported a significant increase in net loss and a decrease in revenue for the first six months of 2025, raising substantial doubt about its ability to continue as a going concern.

Mangoceuticals' Q1 2025 revenue decreased due to platform transition issues, while the company continues to pursue strategic alternatives and secure additional funding.

Mangoceuticals, Inc. reports a net loss of $1.99 million for the third quarter of 2024, with a decrease in revenue due to platform migration issues.

Mangoceuticals, Inc. reported a significant increase in net loss for 2025, alongside a going concern warning, as it navigates strategic shifts into digital assets and new product development.

Mangoceuticals, Inc.'s 2024 annual report reveals a year of strategic shifts, including a subsidiary reorganization and patent acquisitions, amidst ongoing financial challenges and a net loss of $8.7 million.

Mangoceuticals, Inc.'s 10-K filing outlines their business model, financial results, and future plans, including challenges with Nasdaq compliance and reliance on related-party transactions.

Nuclea Energy Inc. and Mangoceuticals, Inc. have entered a definitive agreement to combine, aiming to list Nuclea's advanced nuclear technology on Nasdaq and fund its Morpheus microreactor development.

Mangoceuticals, Inc. announced a business combination agreement with Nuclea Energy Inc. to advance Nuclea's lead-cooled Morpheus microreactor technology.

MANGOCEUTICALS, INC. CEO Jacob D. Cohen increased his beneficial ownership through a discretionary bonus, new stock options, and a convertible note with warrants.

MANGOCEUTICALS, INC. CEO Jacob D. Cohen's stock options were repriced to $0.45 per share on March 16, 2026, a significant reduction from original strike prices, though still above the market closing price.

MANGOCEUTICALS, INC. CFO Eugene M Johnston reported the sale of 3,333 shares of common stock at $1.1653 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

MANGOCEUTICALS, INC. CFO Eugene M. Johnston sold 5,000 shares of common stock for $1.195 per share as part of a pre-arranged 10b5-1 trading plan.

Mangoceuticals is convening a special meeting of stockholders to vote on proposals including amendments to the Series B Convertible Preferred Stock, adoption of the Second Amendment to the Equity Incentive Plan, and other corporate governance matters.

Mangoceuticals, Inc. will hold its annual meeting on June 17, 2024, seeking stockholder approval for director elections, stock issuances, auditor ratification, and potential meeting adjournment.

Mangoceuticals is asking stockholders to approve a reverse stock split to maintain its Nasdaq listing and an amendment to its equity incentive plan to attract and retain key personnel.

Mangoceuticals, Inc. reports significant net losses and declining revenues for recent periods, while pursuing strategic alternatives and facing substantial dilution from ongoing capital raises and related party transactions.

Mangoceuticals, Inc. filed an S-1 registration statement for the resale of up to 2,640,178 shares of common stock by selling stockholders, while reporting significant recurring net losses and a going concern doubt.

Mangoceuticals, Inc. has filed an S-1 registration statement to allow existing shareholders to resell up to 4,461,718 shares of common stock, while the company continues to report significant net losses and faces a lawsuit from Eli Lilly and Company.

Mangoceuticals registers shares for resale by selling stockholders, detailing its growth strategy focused on marketing, telemedicine, and subscription plans.

Mangoceuticals is registering shares for resale by selling stockholders, with proceeds to the company from ELOC and warrant exercises used for working capital.

Mangoceuticals is registering for the resale of over 30 million shares of common stock by selling stockholders, involving commitment shares, ELOC shares, warrant shares, and preferred conversion shares.

Mangoceuticals, Inc. CEO Jacob D. Cohen increased his beneficial ownership to 14.6% through new stock and option grants, while the company secured a convertible loan and warrants from his controlled trust.

Jacob D. Cohen and The Tiger Cub Trust have updated their beneficial ownership in Mangoceuticals, Inc., with Mr. Cohen receiving a 200,000-share bonus, increasing his aggregate stake to 11.0%.

Greenfield Investments, Ltd and Peter M. Karam have jointly disclosed a beneficial ownership of 14.44% in Mangoceuticals, Inc.'s common stock, totaling 515,000 shares.